Wu SY - Search Results

1

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.

Wu SY, Xiao Y, Wei JL, Xu XE, Jin X, Hu X, Li DQ, Jiang YZ, Shao ZM. Wu SY, et al. J Immunother Cancer. 2021 Jul;9(7):e002528. doi: 10.1136/jitc-2021-002528. J Immunother Cancer. 2021. PMID: 34321275 Free PMC article.

2

Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.

Yu KD, Wu SY, Liu GY, Wu J, Di GH, Hu Z, Hou YF, Chen CM, Fan L, Tang LC, Shen ZZ, Wu KJ, Zhuang ZG, Zhang HW, Shao ZM. Yu KD, et al. Among authors: wu kj, wu sy, wu j. Cancer. 2019 Jul 1;125(13):2185-2193. doi: 10.1002/cncr.32057. Epub 2019 Mar 20. Cancer. 2019. PMID: 30892700 Free article. Clinical Trial.

3

Subtype-Guided ¹⁸ F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.

Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G. Wu S, et al. Oncologist. 2020 Apr;25(4):e626-e633. doi: 10.1634/theoncologist.2019-0583. Epub 2019 Dec 11. Oncologist. 2020. PMID: 32297448 Free PMC article.

4

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.

Wei JL, Wu SY, Yang YS, Xiao Y, Jin X, Xu XE, Hu X, Li DQ, Jiang YZ, Shao ZM. Wei JL, et al. Among authors: wu sy. J Immunother Cancer. 2021 Jul;9(7):e002383. doi: 10.1136/jitc-2021-002383. J Immunother Cancer. 2021. PMID: 34281987 Free PMC article.

5

Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.

Yang F, Wu SY, Mo M, Xiao Q, Yang X, Liu YY, Li JW, Shao ZM, Liu GY. Yang F, et al. Among authors: wu sy. Transl Cancer Res. 2020 Jan;9(1):155-165. doi: 10.21037/tcr.2019.11.23. Transl Cancer Res. 2020. PMID: 35117169 Free PMC article.

6

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.

Wu SY, Li JW, Wang YJ, Jin KR, Yang BL, Li JJ, Yu XL, Mo M, Hu N, Shao ZM, Liu GY. Wu SY, et al. Int J Surg. 2023 Jul 1;109(7):1863-1870. doi: 10.1097/JS9.0000000000000331. Int J Surg. 2023. PMID: 37132193 Free PMC article.

7

Repeated core needle biopsy and targeted fine-needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: prospective clinical study.

Wu SY, Li JW, Zhang Y, Wu HL, Mo M, Hu N, Shao ZM, Liu GY. Wu SY, et al. Among authors: wu hl. Br J Surg. 2023 Sep 6;110(10):1264-1266. doi: 10.1093/bjs/znad106. Br J Surg. 2023. PMID: 37252942 No abstract available.

8

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer.

Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Xie Y, et al. Front Oncol. 2021 Jun 8;11:686591. doi: 10.3389/fonc.2021.686591. eCollection 2021. Front Oncol. 2021. PMID: 34168999 Free PMC article.

9

Low rate of positive margins and re-excision after partial mastectomy in highly selected breast cancer patients: A Chinese single-institution experience.

Wu S, Zhu Y, Yang Z, Mo M, Gao H, Yang W, Liu G. Wu S, et al. Oncotarget. 2017 Feb 14;8(7):12225-12233. doi: 10.18632/oncotarget.14686. Oncotarget. 2017. PMID: 28103572 Free PMC article.

10

Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.

Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, Jia X, Wang Y, Mo M, Zhang N, Shen Z, Wu J, Shao Z, Liu G. Zhang Y, et al. Breast Cancer Res Treat. 2018 Apr;168(3):679-686. doi: 10.1007/s10549-018-4660-y. Epub 2018 Jan 13. Breast Cancer Res Treat. 2018. PMID: 29332135 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,864 results

Search Page